Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Atezolizumab,"Non-small cell lung cancer, locally advanced or metastatic, high (>50%) PD-L1 expression, 1st line monotherapy",Atezolizumab (Tecentriq),Hospital,Oncology Agents and Immunosuppressants
